What the GPhC Now Expects from GLP-1 Prescribing and Dispensing: A 2026 Compliance Brief
GPhC standards for online weight-loss prescribing have tightened materially since February 2024. Here's the current state of the rules pharmacists, prescribing services and pharmacy owners need to meet — and the inspection patterns that follow them.
Key takeaways
- The General Pharmaceutical Council (GPhC) has progressively tightened standards for online weight-loss prescribing since its February 2024 guidance and the joint regulatory statement issued with the CQC and MHRA. The rules are no longer aspirational — they are the inspection benchmark.
- Three requirements now sit at the centre of compliance: objective verification of clinical eligibility, two-way consultation, and documented clinical decision-making. None can be substituted by patient questionnaires alone.
- The September 2025 update to Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet raised the bar for governance, supervision and audit. Pharmacy owners are accountable, not only the prescribing pharmacist.
- The most common enforcement trigger is high-volume online prescribing without per-pharmacist safeguards. Inspectors look at volume-to-staffing ratios as the leading signal of risk.
- Compliance and commissioning are converging. ICB tender specifications and OPIP procurement requirements increasingly mirror GPhC expectations directly, meaning the same evidence pack supports both regulatory inspection and NHS-route commissioning.
The General Pharmaceutical Council regulates pharmacists, pharmacy technicians and registered pharmacies in Great Britain. For most prescribing services, GPhC oversight has historically operated in the background — periodic inspection, quiet enforcement, occasional remedial action. The GLP-1 prescribing surge of 2023–24 changed that.
In February 2024, the GPhC issued a public statement on weight-loss medicines online, jointly framed with parallel statements from the Care Quality Commission and the Medicines and Healthcare products Regulatory Agency. That statement was the inflection point. What had been guidance suggesting that online questionnaires alone were inadequate became guidance specifying the additional steps required. What had been a tolerated grey area — prescribing weight-loss medication based on patient self-declaration — became a hardline non-compliance.
This article sets out what the GPhC now requires from any pharmacy or prescribing service supplying GLP-1 medicines, where current services are most often falling short, and how compliance now intersects with the wider commissioning landscape.
Why the rules tightened
The trigger was scale. By early 2024 a small number of online pharmacies and prescribing platforms were dispensing GLP-1 medicines at volumes the regulator could not reconcile with the standards in force. Patients were being approved on the basis of self-declared weight and height alone. Body mass index calculations were being accepted without verification. Contraindications were being missed because the consultation infrastructure could not surface them. Pharmacists were signing off prescriptions in volumes that suggested per-patient time was measured in seconds rather than minutes.
The Joint Statement from the GPhC, CQC and MHRA in February 2024 was the public response. It was followed by a programme of inspections, enforcement action against named services, and the formal updating of the GPhC’s online-services guidance over the eighteen months that followed. The most recent revision of Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet in September 2025 incorporates the lessons from those inspections and tightens the supervision and governance expectations on pharmacy owners.
The direction has been consistent across every revision: the standards are not new in principle, but the bar for evidencing compliance has moved upward continuously.
The February 2024 weight-loss guidance — what it actually says
The GPhC’s February 2024 statement specified what an acceptable consultation for weight-loss medicines must include. The requirements are unambiguous and have been reinforced rather than softened in subsequent guidance.
Identity verification. The patient’s identity must be verified — not assumed from form-completion. Acceptable verification routes include photographic identification cross-checked against a video or live consultation, NHS Login (where available), or equivalent identity-assurance frameworks. Email-only or address-only verification is insufficient.
Objective verification of clinical eligibility. Weight, height and BMI cannot be accepted on patient self-declaration alone. Evidence must be obtained — typically photographic verification of weight on a scale, photographic confirmation of height, GP record corroboration, or an in-person measurement. The pharmacist must be able to defend the BMI on which the prescribing decision was made if asked to in inspection.
Two-way consultation. A consultation must be a genuine two-way clinical interaction, not a unidirectional questionnaire. Acceptable formats include real-time video, real-time written exchange (live chat), structured asynchronous written consultation with documented clarification rounds, or telephone consultation. A multiple-choice questionnaire submitted by the patient with no clinician follow-up is not a consultation.
Documented clinical decision-making. Every prescribing decision must be recorded with sufficient clinical detail to evidence the basis on which it was made. Decisions not to prescribe must also be documented — the absence of declined prescriptions in the records of a high-volume service is itself a flag.
Safeguards for high-volume prescribing. Pharmacy owners must have governance arrangements proportionate to the scale of supply. Per-pharmacist daily limits, peer-review sampling, and structured oversight are required where volumes warrant them. Volume that exceeds the pharmacist’s capacity for safe individual review is non-compliant by definition.
Restrictions on co-supply. Weight-loss medicines must not be supplied alongside contra-indicated products — a particular focus on compounded products, off-licence preparations, and supplements positioned as therapeutic adjuncts. The clinical judgment on what is co-prescribed sits with the pharmacist, but the operational guardrails sit with the pharmacy owner.
These six requirements form the substrate of every subsequent GPhC inspection of GLP-1 services. Services compliant with all six pass. Services compliant with five face conditions. Services compliant with fewer face suspension or removal of registration.
Operating Online — the September 2025 update
The 2025 revision of Guidance for registered pharmacies providing pharmacy services at a distance moves the focus from the prescribing pharmacist to the pharmacy owner. It is the governance counterpart to the February 2024 clinical-conduct guidance.
Pharmacy owners are now expected to:
- Maintain governance arrangements proportionate to scale. A high-volume online service must have governance equivalent to a high-volume bricks-and-mortar service: clinical leadership, named accountable pharmacist, defined responsibilities, scheduled review cycles.
- Risk-assess the remote service. Identify the patient-safety risks specific to the model — verification gaps, supervision distance, escalation latency — and document the mitigations.
- Evidence supervision arrangements. Demonstrate that pharmacist supervision meets the pharmacist supervision regulations and that the named supervising pharmacist has effective oversight in practice, not just on paper.
- Audit dispensing. Maintain audit trails sufficient for inspection, including the specific pharmacist who authorised each supply and the clinical record at the time.
- Report patient-safety incidents. Maintain a patient-safety reporting workflow and surface incidents to the GPhC where required.
The shift in emphasis is meaningful. Where the February 2024 guidance was directed at the consultation, the September 2025 update is directed at the operating model. A pharmacist consulting compliantly inside a non-compliant operating model is still in a non-compliant service. The pharmacy owner is responsible for the model.
Supervision and pharmacist accountability
The supervision regime tightened materially in 2024–25 with the implementation of the updated pharmacist supervision regulations under the Pharmacy (Responsible Pharmacists) framework. The relevant change for online services is that pharmacist supervision must be effective in fact, not nominal in form.
This has practical implications. A “responsible pharmacist” who is named on paper but supervises five different premises in different cities cannot evidence effective supervision of any one of them. A supervising pharmacist whose daily authorisation volume is incompatible with safe individual review of each prescription cannot evidence the substance of supervision. A supervisory model that depends on automated approvals with periodic pharmacist review does not meet the regulations for the prescribing of GLP-1 medicines.
The GPhC has been explicit that volume-vs-staffing ratios are the single most consistent signal it uses to identify services for inspection. A service whose published prescribing volumes are inconsistent with the pharmacist headcount on its register will be reviewed. The defence in inspection is the audit trail showing that each supply received the pharmacist time the regulations require.
The joint regulatory framework
GLP-1 services sit in the overlap of three regulators. Each has a distinct remit but they coordinate, share intelligence, and sometimes inspect jointly.
The GPhC regulates the pharmacy, the pharmacist and the dispensing process. It is the primary inspector for any registered pharmacy supplying GLP-1 medicines.
The CQC regulates regulated activities including the prescribing service where it is provided through a registered healthcare provider. The CQC inspects the prescribing service for clinical governance, safe prescribing, and patient outcomes. The CQC’s 2024 thematic review of independent prescribing for weight management is the operational template for that inspection.
The MHRA regulates the medicines themselves and the medical devices used in their administration or in supporting services. MHRA jurisdiction extends to digital health tools classified as software medical devices — including patient-facing apps that surface clinical recommendations or symptom-driven escalations.
The Joint Statement of February 2024 explicitly committed the three regulators to coordinated action on weight-loss medicines online. In practice, this means a service can be examined from clinical (CQC), pharmacy (GPhC) and medicines/devices (MHRA) angles either sequentially or jointly. Compliance documentation that satisfies one regulator but contradicts another is a near-guaranteed enforcement trigger.
What inspectors actually look at
GPhC inspectors arrive with a structured set of questions and a sample-based review approach. The inspection follows a pattern.
Sample of prescribing records. Inspectors typically pull a sample of prescribing decisions across a defined period and review the clinical record for each. They look for the consultation evidence, the verification of eligibility, the documented rationale, and the dispensing trail. They check that decisions not to prescribe are present in proportionate numbers.
Consultation evidence. They look at the actual consultation records — the chat transcripts, the video records (if retained), the written exchanges. They check that the consultation was bidirectional and clinically substantive, not formulaic or unidirectional.
Volume vs staffing ratios. They reconcile the published prescribing volumes against the pharmacist register and the supervision arrangement. Discrepancies trigger deeper review.
Patient safety incident logs. They review the incident log for completeness and follow-up. The absence of incidents in a high-volume service is itself anomalous and prompts questions about under-reporting.
Governance and audit documentation. They review the pharmacy owner’s governance documentation: standard operating procedures, clinical-leadership arrangements, supervision logs, audit trails, incident response procedures.
Co-supply patterns. They look for patterns of co-supply with contra-indicated or non-evidenced products, particularly compounded products and supplements positioned as therapeutic adjuncts.
The inspection produces a report that the pharmacy owner has a defined window to respond to. Conditions, undertakings, suspension or removal of registration follow when responses are inadequate.
Common compliance gaps
In services that fail or face conditions, the failures cluster.
Self-declared BMI. The single most common failure: a service that has continued to accept patient-declared weight without independent verification. Often this is operationalised as an honest oversight — the service was set up before February 2024 and the verification step was never retrofitted.
Questionnaire-as-consultation. A service that markets a “consultation” but operates a one-direction questionnaire with no clinician engagement before dispensing.
Volume incompatible with supervision. A service whose published prescribing volume is mathematically incompatible with safe pharmacist review at the staffing level disclosed.
Undocumented decision-making. A service whose clinical records contain the prescribing decision but not the basis for it. Inspectors looking for “why this patient, this dose, this medication” find the dispensing record but not the rationale.
No follow-up after dispatch. A service that supplies the medication but has no documented post-dispatch safety check, escalation pathway, or follow-up consultation. The GPhC and CQC both view post-dispatch safety as a continuing pharmacist responsibility, not an optional add-on.
Co-supply with adjuncts. Particularly compounded preparations, off-licence products, and supplements marketed alongside the GLP-1 medication. Co-supply attracts regulatory attention even where individual products would not.
Outdated documentation. A service whose standard operating procedures, supervision arrangements, or governance documentation pre-dates the February 2024 guidance and has not been updated to reflect the current standard.
A service that addresses all of these passes inspection on the substantive points. A service that addresses none should not be operating in 2026.
A practical compliance checklist
For a prescribing or dispensing service reading this and recognising gaps, the practical remediation path covers seven areas.
1. Verification. Implement photographic or video verification of weight at consultation. Document the verification step in the clinical record. Retain the evidence for the regulatory retention period.
2. Consultation. Ensure every consultation is two-way and clinically substantive. Document the consultation. Retain the consultation record. Where the consultation is asynchronous, document the clarification rounds.
3. Documentation. Record the clinical rationale for each prescribing decision in sufficient detail that an inspector can reconstruct the basis on which it was made. Record decisions not to prescribe equally.
4. Volume and supervision. Review the volume-to-staffing ratio. Reduce volume or increase supervision capacity until the ratio supports safe individual review. Document the supervision arrangement and the actual time each pharmacist spends per decision.
5. Governance. Update the standard operating procedures to reflect the September 2025 Operating Online guidance. Document clinical leadership, supervision arrangements, audit cycles and incident-response procedures.
6. Post-dispatch safety. Implement and document the post-dispatch safety check workflow. Make the escalation pathway clinician-linked, time-bound, and auditable.
7. Co-supply audit. Review the product range for contra-indicated or non-evidenced co-supply patterns. Remove or document the clinical justification.
This is not a complete compliance manual. It is the gap-closure checklist that converts a pre-2024 service into a service compatible with current GPhC, CQC and MHRA expectations.
Where this is headed
Three trends will shape GPhC GLP-1 oversight through 2026 and beyond.
Continued enforcement on high-volume online prescribers. The GPhC has stated, repeatedly and publicly, that volume-vs-supervision discrepancy is the leading inspection trigger. Services that have not adjusted volumes or staffing in response to the 2024–25 guidance updates will continue to be the focus of enforcement action.
Tighter convergence of GPhC, CQC and MHRA inspection. The Joint Statement framework is producing increasingly coordinated inspection patterns. Services responding to one regulator with documentation that contradicts another are flagged automatically. Compliance documentation needs to be internally consistent across all three regulatory framings.
Convergence with NHS commissioning standards. ICB tender specifications and OPIP procurement requirements increasingly mirror GPhC expectations directly: objective verification, documented consultation, structured outcome capture, audit-grade governance. The same evidence pack now supports regulatory inspection and commissioning bids. For services aiming at the NHS-route opportunity, the GPhC standards are the floor, not the ceiling.
The implication for GLP-1 prescribing and dispensing services is that compliance is no longer a defensive activity. It is the precondition for the commissioning opportunities that are forming around it. Services investing in evidenceable compliance now are positioned for both inspection and procurement. Services treating compliance as a static cost are choosing not to compete in the market that is emerging.
Cadence Health supports GLP-1 prescribing and dispensing services with the documented infrastructure required for current GPhC, CQC and MHRA expectations: structured consultation evidence, SNOMED-coded clinical decision records, post-dispatch safety workflow, clinician-linked escalation, MHRA Class I SaMD registration with active hazard log, and audit-ready governance documentation. The same evidence pack supports inspection and ICB / OPIP commissioning. Get in touch at hello@cadencehealth.uk.
References: General Pharmaceutical Council Statement on weight-loss medicines (February 2024); GPhC, CQC and MHRA Joint Statement on weight-loss medicines online (February 2024); GPhC Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet (most recent revision September 2025); GPhC Standards for Registered Pharmacies (2018, current); GPhC Standards for Pharmacy Professionals (2017, current); Pharmacy (Responsible Pharmacists) Regulations and updated supervision framework (2024–25); CQC thematic review of independent prescribing for weight management (2024); MHRA guidance on Software as a Medical Device classification; NICE TA1026 and TA875 wraparound conditions; NHS England Interim Commissioning Guidance for TA1026 (March 2025).